<DOC>
	<DOCNO>NCT00166205</DOCNO>
	<brief_summary>The purpose study determine whether Swedish Adjustable Gastric Band ( SAGB ) safe , effective achieve weight loss patient Morbid Obesity .</brief_summary>
	<brief_title>Safety Effectiveness Study The Swedish Adjustable Gastric Band ( SAGB ) Treatment Morbid Obesity</brief_title>
	<detailed_description>Surgical treatment morbidly obese patient consider reasonable option achieve weight loss conservative measure , diet exercise fail . Not weight loss achieve , also reduction / resolution patient 's co-morbidities associate excess weight . Adjustable gastric band provide less invasive , reversible bariatric surgery option . The SAGB commercially available outside United States indication since 1996 . Commercial availability lead extensive literature support safety effectiveness SAGB . Given available literature , prospective , single arm , multicenter , study heterogeneous population morbidly obese subject U.S. conduct .</detailed_description>
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Obesity , Morbid</mesh_term>
	<criteria>Able comprehend , follow give sign informed consent ; 18 60 year age ( inclusive ) ; Five year history morbid obesity ; Body Mass Index ( BMI ) &gt; 40 kg/m2 &lt; 55 kg/m2 , BMI &gt; 35 kg/m2 &lt; 40 kg/m2 one significant medical condition relate obesity ( comorbid condition type 2 diabetes , hyperlipidemia , obstructive sleep apnea , hypertension , metabolic syndrome , osteoarthritis hip knee ) subject treat , generally expect improve , reverse , resolve weight loss . 100 lb . overweight 1.5 time ideal weight ; Documented failure conservative , nonsurgical mean weight reduction within one year prior Screening Visit , include failure supervise diet , exercise behavior modification program , pharmacologic therapy ; Willing commit significant lifestyle change include diet , eating , exercise habit duration clinical trial ; Able commit longterm followup , include band adjustment visit : Living within contiguous U.S. within 100 mile radius study center ; Absence significant psychopathology could limit subject 's ability understand procedure , comply medical , surgical , and/or behavioral recommendation , document screening assessment ; Agrees refrain type reconstructive surgery would affect body weight abdominal lipoplasty liposuction , mammoplasty , removal excess skin followup period follow SAGB placement ; Candidate surgical weight loss intervention ( i.e. , meet accept health criterion major surgery ) . Women childbearing potential practicing effective method birth control pregnant lactating ; Previous malabsorptive restrictive procedure perform treatment obesity ; Documented history drug and/or alcohol abuse within two year Screening Visit ; History impair mental status include , limit active substance abuse , history schizophrenia , borderline personality disorder , uncontrolled depression , suicidal attempt within past two year current suicidal tendency ideation ; Presence follow medical condition ; Inflammatory diseases gastrointestinal tract , include severe intractable esophagitis , gastric ulceration , duodenal ulceration , specific inflammation Crohn 's disease active within past 10 year ; Congenital acquire anomaly GI tract , include atresias stenosis , Severe cardiopulmonary disease serious organic disease make subject highrisk surgical candidate ; Uncontrolled hypertension ; Portal Hypertension ; Uncontrolled Diabetes Mellitus ; Chronic acute upper gastrointestinal bleeding condition , e.g . gastric esophageal varix ; Cirrhosis ; Congenital acquire intestinal telangiectasia ; Esophageal gastric disorder include severe preoperative reflux , dysmotility , Barrett 's Esophagus ; Presence hiatal hernia ; Prior surgery foregut include hiatal hernia repair prior gastric surgery ; Chronic pancreatitis ; Immunocompromised result chronic oral steroid use , chemotherapeutic agent , immune deficiency disorder ; Conditions , opinion investigator , may jeopardize subject 's wellbeing and/or soundness clinical study ; History presence preexist autoimmune connective tissue disease , i.e. , systemic lupus erythematosus scleroderma ; Presence terminal illness life expectancy &lt; 5 year ; Use prescription counter weight reduction medication supplement within one month Screening Visit duration study participation ; Acute chronic infection ( localized systemic ) ; Known suspect allergy silicone material contain Swedish Adjustable Gastric Band ; History intolerance implant device ; Not ambulatory ; Participation another clinical trial within 8 week Screening Visit duration trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Obesity , Morbid</keyword>
	<keyword>Obesity</keyword>
	<keyword>Body Weight</keyword>
</DOC>